Dr Reddy’s ends Novartis India distribution pact after ownership change

Dr Reddy’s Laboratories has terminated its distribution and promotion agreement with Novartis India for select domestic brands following a change in Novartis India’s controlling shareholding. Dr Reddy’s will continue commercialising the covered portfolio until September 30, 2026.

— Source publishedFri, 7 Aug, 2026, 23:52 IST·First seen Sat, 8 Aug, 2026, 00:01 IST·Source CNBC-TV18 · Companies

What happened

Dr. Reddy’s Laboratories · Dr Reddy’s terminated its distribution and promotion agreement with Novartis India for select domestic brands following a change in

Key facts

  • February 11, 2022
  • September 30, 2026
  • 0.09%
  • ₹1,172

Why this matters

Novartis India’s ownership change and exit from the distribution arrangement may open opportunities for Dr Reddy’s to pursue replacement in-licensing, brand acquisitions, or new domestic commercial partnerships.

What to watch

  • Announcement of the specific brands covered and their contribution to Novartis India and Dr Reddy's domestic sales.
  • Identity and economics of Novartis India's replacement commercial partner, if any.
  • Changes in Novartis India sales-force hiring, distributor appointments, or tender participation.
  • Evidence of inventory build, channel-stock normalization, price revisions, or supply interruptions ahead of September 2026.
  • Dr Reddy's domestic formulations guidance and commentary on revenue or field-force impact from the exit.
  • Further disclosures on the ownership change and whether it prompts broader portfolio or operating-model restructuring at Novartis India.
  • Novartis India is likely to disclose a successor distribution, promotion, or internal commercialisation arrangement well before the September 2026 cutoff.
  • Dr Reddy's may revise field-force deployment and distributor incentives as the covered brands become a declining-share portfolio.
  • Both companies may increase transition inventory planning and account communication to protect prescription continuity.
  • Competitors in affected therapy categories may target doctors, hospitals, and chemists in regions where the handover appears least certain.